In this article, we will delve into the fundamental analysis of leading pharma stocks Catalyst Pharmaceuticals, Inc. (CPRX) and Teva Pharmaceutical Industries Limited (TEVA). Through this analysis, it becomes apparent that TEVA is a better value stock for August. However, before delving into the factors that underlie this positive outlook for TEVA, let's first explore the broader landscape of the pharmaceutical industry.
The pharmaceutical sector has flourished due to robust demand, particularly for COVID-19 treatments and vaccines. The emergence of novel approaches like cell and gene therapy, mRNA vaccine technology, evolving supply chains, and shifts in the product landscape further fuels this growth.
